Inovio Pharmaceuticals (INO) stock was higher Thursday after announcing its Covid-19 vaccine offers a strong immune response against variants. Shares of the company were trading higher 2.24% to $9.05 a share on Thursday.
What's Happening With Inovio?
The biotechnology company was pleased to announce the results of a study focusing on the human immune responses induced by Inovio's DNA vaccine candidate for COVID-19, INO-4800, against all major variants. Moreover, its drug showed a strong T cell response against all spike protein variants tested, including the UK, South African and Brazilian variants.
Dr. J. Joseph Kim, INOVIO's President & CEO, said, "These results are consistent with our expectation that INO-4800, which was found to be well-tolerated and able to produce a balanced immune response in our Phase 1 trial, is able to generate both neutralizing antibodies and robust T cell responses – both of which will be essential to protect against the emerging variants of concern."
What Does This Mean For Inovio?
Inovio, one of many biotech companies who were early contenders to develop a vaccine against Covid-19, believes the combination of robust T cell responses in conjunction with neutralizing antibody responses offers an important defense against both emerging and potential future viral variants. It plans on reporting Phase 2 results in the second quarter, according to its CEO Mr. Kim.
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon optimized plasmids that have ability to help break the immune system's tolerance of cancerous or infected cells and facilitate cross-strain protection against unmatched and matched pathogen variants.
INO has an Overall Score of 36. Find out what this means to you and get the rest of the rankings on INO!
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.